A system intended to meet authority and customer requirements is now on site

NanoEcho has now successfully completed the detailed product development phase. The work has resulted in a system that has been developed to meet both the authorities' and customers' requirements. This system consists of parts manufactured by the company's selected partners and key suppliers, Vermon and us4us. The system is now on site at the company's premises in Lund, ready for integration and evaluation.

The detailed product development phase is now complete and the company's product development work is moving into an integration and evaluation phase. In this phase, all the parts of the system, that the company has developed together with its partners, are assembled and the system software will be developed.
Once the integration work is completed, the system will be evaluated with regard to authority and customer requirements. The company's ambition is to replace the prototype system currently used in the ongoing investigator-led clinical development studies with this new system in 2023.

"We have had our sights set on this milestone all year, and today I am extremely proud that we now have our system assembled on site here in Lund. Both our team and our partners have done a very impressive job, developing and producing this system to meet highly set medical technical requirements in such a short time. When we replace the prototype system with this system in the ongoing clinical development studies, the goal is to increase the quality of the data we obtain," says Linda Persson, CEO of NanoEcho.

Start of an investigator-led clinical development study at Skåne University Hospital

An investigator-led clinical development study has started at Skåne University Hospital in Malmö. In this context, the first examination of resected rectal cancer tissue has been performed with the NanoEcho diagnostic system.

NanoEcho is developing a system that intends to improve the diagnosis of rectal cancer spread to nearby lymph nodes, an important marker of cancer progression. Since 2021, there has been an ongoing investigator-led clinical development study on resected rectal cancer tissue at Sahlgrenska University Hospital in Gothenburg. Now an investigator-led study has also started at Skåne University Hospital (SUS) in Malmö. Using NanoEcho's system, these developmental studies aim to examine rectal cancer at different stages and located anywhere in the rectum.

The first patient at SUS in Malmö has been recruited and the first examination was carried out with the company's diagnostic prototype system on 3rd November. The study, which will include approximately 40 rectal cancer patients, is lead by Henrik Thorlacius, surgery professor at Lund University and Chief Physician in surgery at Scania University Hospital in Malmö. Patients will undergo usual routine standard surgery and the tissue removed during surgery will be examined with NanoEcho's system before being submitted for pathological analysis.

“We hope that NanoEcho´s instrument can identify lymph nodes containing cancer cells, which could improve the diagnosis of rectal cancer. If we can, we will proceed with further clinical studies whereby NanoEcho's instrument will be evaluated on patients before surgery”, says Henrik Thorlacius.

“Starting now these two investigator-led clinical development studies represents a major milestone. The goal is that together they will provide a comprehensive analysis of the system's performance and contribute important information to the product development of our commercial system”, says Linda Persson CEO of NanoEcho.

Link to a film where Henrik Thorlacius explains more about the investigator-led clinical development study.

Nanoecho.se använder cookies för att förbättra hemsidans funktionalitet för dig som användare. Är det okej?